Series-5824 (MT)

Through a two-year lead optimization collaboration, DNDi and Mitsubishi Tanabe Pharma (MTPC) aim to optimize a novel and very promising T. cruzi active series identified through high-throughput screening of 51,200 compounds in MTPC’s proprietary library. To date, the series has progressed to the lead stage. Project partners plan to chemically derivatize the lead series using a well-defined and diversified medicinal chemistry strategy to improve its in vitro potency against the T. cruzi parasite while maintaining its favourable drug metabolism and pharmacokinetic properties and mitigating any safety liabilities. In parallel, DNDi and MTPC will work to elucidate the mechanism of action of the series with the expert support of University of Dundee, and make use of this information to guide the lead optimization programme.